Table 3

Relative risk of death from breast cancer according to MVD, stratified for molecular subtypes

MVD, microvessels/mm2 Luminal AHER2 type5NPBP
Two visual fields with the highest count
 Unadjusted HR* (95% CI)1.09 (1.02 to 1.17)1.05 (1.02 to 1.09)1.09 (1.03 to 1.16)1.03 (0.98 to 1.07)
 Adjusted† HR (95% CI)1.16 (1.05 to 1.28)1.10 (1.05 to 1.15)1.09 (1.01 to 1.18)1.00 (0.95 to 1.06)
Four visual fields in consecutive order
 Unadjusted HR* (95% CI)1.10 (1.02 to 1.19)1.09 (1.04 to 1.14)1.08 (1.01 to 1.15)1.03 (0.98 to 1.08)
 Adjusted HR† (95% CI)1.18 (1.05 to 1.32)1.15 (1.07 to 1.24)1.11 (1.02 to 1.22)1.00 (0.94 to 1.07)
Ten visual fields
 Unadjusted HR* (95% CI)1.12 (1.02 to 1.22)1.07 (1.03 to 1.12)1.10 (1.02 to 1.18)1.06 (0.96 to 1.16)
 Adjusted HR† (95% CI)1.19 (1.05 to 1.35)1.14 (1.07 to 1.21)1.17 (1.04 to 1.32)0.99 (0.88 to 1.10)
  • *HR per 10 vessels increase.

  • †Adjusted for age, year of diagnosis, tumour size, lymph node status and grade.

  • BP, basal phenotype; HER2, human epidermal growth factor receptor 2; MVD, microvessel density; 5NP, five negative phenotype.